55.32USD-4.26%Mkt Cap: 3.33B USDP/E: —Last update: 2026-06-01
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead pr…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap3.33B USD
Enterprise Value3.14B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-105.43M USD
Revenue/Share—
Last Price55.32 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees68
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-23.77
PEG—
EV/EBITDA-23.56
EV/Revenue—
P/S—
P/B6.08
EPS (TTM)-1.93
EPS (Forward)-2.46
52W Range
10.6456% of range91.00
52W High91.00 USD
52W Low10.64 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.48%
ROA-21.58%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-88.21M USD
CapEx (TTM)209.00K USD
FCF Margin—
FCF Yield-1.69%
Net Debt-387.02M USD
Net Debt/EBITDA2.90
Balance Sheet
Debt/Equity0.00
Current Ratio23.76
Quick Ratio23.38
Book Value/Sh9.626 USD
Cash/Share6.447 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateAug 28, 2024
Splits
Last Split1:12
Split DateSep 3, 2024
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)142.17 USD
Target Range100.00 USD – 200.00 USD
# Analysts12
Ownership
Shares Out.60.31M
Float51.05M
Insiders1.29%
Institutions87.90%
Short Interest
Short Ratio2.8d
Short % Float15.80%
Short % Out.10.37%
Shares Short6.25M
Short (prev mo.)5.54M
Technical
SMA 5059.64 (-7.2%)
SMA 20035.01 (+58.0%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)1.94M
Avg Vol (10d)1.30M
Technical Indicators
RSI (14)43.0
MACD-1.0788
MACD Signal-0.1049
MACD Hist.-0.9739
BB Upper69.78 USD
BB Middle62.23 USD
BB Lower54.67 USD
BB Width24.28%
ATR (14)3.784 USD
Vol Ratio (20d)0.43x